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ABSTRACT
Background: Bronchial Asthma (BA) is a chronic inflammatory of the airways. [1] It is generally
known that asthma can cause an impact on a patient’s Quality of Life (QoL), mostly in a negative
manner. To perceive the impact it has on the population, ‘Questionnaires on Quality of Life’ in
asthmatic patients were made. Improving the QoL of patients with asthma mainly aims at reducing
the risk of exacerbation and preventing morbidity related to asthma. Drug Utilization studies are
important in order to assess the current prescription patterns against standard guidelines and can
help in rationalizing the management. The economic burden of asthma has increased drastically
across the globe over several decades. Patients’ knowledge, awareness of the disease, and low cost
of therapy are key factors in improving quality of life. [2]
Objectives: To study the Drug Utilization, direct costs and the QoL of asthmatic patients.
Methods: A prospective study was conducted among 46 Bronchial asthma patients with and
without comorbidities who visited the Respiratory Out-patient department in Kasturba Hospital
after obtaining the ethical clearance. The study aimed at assessing the QoL, drug utilization
patterns, and direct cost of therapy. Quality of Life was measured using the Asthma Quality of
Life Questionnaire (AQLQ) and the direct cost of therapy was analyzed using the medications
prescribed by the physicians, consultation fee and lab charges. [3] Patient were given an AQLQ
along with an informed consent form (ICF), taking the proper consent of the patient, Participation
Information Sheets (PIS) was provided regarding the information on the project being conducted.
Each patient was given 10-15 minutes to sign the ICF and complete the AQLQ. The information
obtained from the patient was transferred from hard copies of Case Report Forms (CRFs) to SPSS
20 and analyzed.
Results: 57 patient files were collected out of which 11 files came under exclusion criteria, thus
46 patients’ data was collected. Mean age of the study population (N = 46) was 40.85 ± 10.02
years. It was found that 67% of the study population were females and 33% were males. 56.5% of
patients had comorbidities whereas 43.5% did not. FEV1 (post) values taken show that 45.6% of
patients have an obstruction. The mean Overall AQLQ score was 4.99 ± 1.24, mean Activity
Limitation score was 4.83 ± 1.33, mean Symptoms score was 5.11 ± 1.41, mean Emotional
Function score was 5.22 ± 1.31 and mean Environmental Stimuli score was 4.66 ± 1.55. These
values along with FEV1 (post) values show that moderate impairment is seen among the patients.
Patients without comorbidities had a better QoL (5.17 ± 1.38) than in patients with comorbidities
(4.86 ± 1.12). Patients who were literate had a higher QoL than the illiterate patients. The average
total cost of treatment, drug cost and lab charges in 46 patients were found to be 2252±1057,
1142.15 ± 484.35 and 920.33 ± 902.31 respectively. The average cost of therapy was found to be
high in the case of patients with co-morbidities.
Conclusion: The results of the study suggest that more studies need to be conducted on QoL of
patients and educate the patients further on the disease knowledge and medication knowledge thus
improving their quality of life and reducing the average cost of therapy.
1

INTRODUCTION
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1. INTRODUCTION
1.1 Definition
BA is a chronic inflammatory disorder of the airways in which many cells and cellular elements
play a role. In particular, mast cells, eosinophils, T-lymphocytes, macrophages, neutrophils, and
epithelial cells. In susceptible individuals, this inflammation causes recurrent episodes of
wheezing, breathlessness, chest tightness, and coughing, particularly at night or early morning [4].
1.2 Epidemiology
Around 339 million people across the globe, suffer from asthma and this number will rise to around
100 million more people being affected by 2025. According to GINA 2018 report, out of 1.31
billion people in India, 6% of children and 2% of adults have asthma. Globally, asthma has been
ranked 16th and 28th among years lived with disability and a leading cause of the burden of disease
respectively. Worldwide, deaths from this condition have reached over 420,000 in 2016 with more
than 1000 per day. About 80% of deaths occur mainly in low and lower-middle-income countries.
The rate of asthma is increasing as communities adopt western lifestyles and become urbanized [5].
Global prevalence (%) of Clinical Asthma includes mainly the countries of Africa, the Americas,
Eastern Mediterranean, Europe, South East Asia, Western Pacific, and a total global percentage [6].

Prevalence (%) of clinical asthma
Western Pacific
23%
South East Asia
13%

Africa
16%
Americas
17%
Eastern
Mediterranean
11%

Europe
20%

Figure 1. Global prevalence (%) of Clinical Asthma
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1.3 Burden of Asthma
A rising burden of Asthma is observed in countries of all financial levels. It is considered both in
terms of direct medical cost (i.e. hospital admissions, cost of pharmaceuticals, etc.) and indirect
medical cost (i.e. time lost from work, premature death, etc.) [7]. Both social and economic
perspectives are required in terms of evaluation of cost for optimal treatment and patient care.
Economic evaluations of asthma have been done in many countries. In the U.S., a study was
published in the American Journal of Respiratory and Critical Care Medicine which showed a 20year cost of uncontrolled asthma which estimated to exceed $963 billion. But there are only limited
population-based studies. In South India, a study was published in Lung India where the annual
cost of asthma treatment was found to be 18,737 INR [8]. The majority of the cost would be out of
their own pockets as there is no proper insurance system developed in India.

4

2. NEED FOR STUDY
Even with the progressing rise in asthma, there are only a few studies done on Drug Utilization
patterns, QoL, and cost in India. In order to understand the effect of medications, a questionnaire
was administered to assess QoL and the objective data generated determined their functional,
emotional, environmental, and activity limitation on a daily basis.
Drug Utilization study aims at assessing the QoL in asthma patients, to determine their functional
problems, and to find the association it shared with patient demographics as there are only a few
studies done on QoL on asthma patients in India.
The cost of therapy is a key factor in low socio-economic patients for obtaining medications
planned out by physicians and the subsequent visits. There is a need for patients, doctors,
administrators, pharmacists, nurses to be provided with an estimate of the direct cost of therapy
which could be used to determine a cheaper and affordable drug regimen to poor patients without
compromising on the quality. The economic data obtained can be utilized to determine the burden
on patients on a day to day basis that may have a direct effect on the patient’s QoL.
Hence, there is a need for more studies to be done to emphasize the importance of drug utilization,
QoL, and cost to find out the probable causes of a low QoL which can help health care
professionals to intervene in a patient-specific approach to improve the outcome.

5

AIMS & OBJECTIVES
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3.0 AIMS AND OBJECTIVES:
Primary objectives:
1. To study drug utilization patterns in patients with Bronchial Asthma.
Secondary objective:
1. To study the quality of life among bronchial asthma patients.
2. To determine the cost of therapy for bronchial asthma patients.

7

LITERATURE REVIEW
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4. REVIEW OF LITERATURE
Bronchial Asthma is defined as a chronic inflammatory disorder of the airways where many cells
and cellular elements have an important role especially mast cells, eosinophils, T-lymphocytes,
macrophages, neutrophils, and epithelial cells [4]. It is associated with hyper-responsive reaction
due to exposure to various risk factors resulting in the obstruction and airflow limitation of the
airways. The most common risk factors include exposure to allergens (includes allergy to certain
animals with fur, insects, dust, pollen, food, etc.), irritants in the air (such as occupational irritants,
tobacco smoke, strong odors, chemical irritants) respiratory (viral) infections, extreme weather
conditions, extreme exercise, strong emotional factors and drugs including Non-Steroidal AntiInflammatory Drugs (NSAIDs)[9]. Asthma presents with symptoms of breathlessness, wheezing,
chest tightness, and coughing, particularly at night or early morning [10].
According to Global Initiative for Asthma (GINA) and National Asthma Education and Prevention
Program (NAEPP) guidelines, asthma is classified into 4 groups based on severity: intermittent
asthma, and mild, moderate, and severe persistent asthma [11].
INTERMITTENT

MILD
PERSISTENT

MODERATE
PERSISTENT

SEVERE
PERSISTENT

SYMPTOMS

≤ 2 days/week

Daily

NIGHTTIME
AWAKENINGS
RESCUE
MEDICATION USE

≤ 2 x month

>2 days/ week
but not daily
3-4 x month

≤ 2 days/ week

>2 days/ week

>1 x week, but
not nightly
Daily

Throughout the
day
Often 7 x week

INTERFERENCE
WITH NORMAL
ACTIVITY
LUNG FUNCTION
*Normal FEV1/FVC:
8-19 Y (85%)
20-39 Y (80%)
40-59 Y (75%)
60-80 Y (70%)

None

Minor

Some

Extreme

FEV1 > 80%
FEV1/FVC normal

FEV1 > 80%
FEV1/FVC
normal

FEV1 60-80%
FEV1/FVC
reduced 5%

FEV1 < 60%
FEV1/FVC
reduced > 5%

EXACERBATIONS

Brief

May affect
activity and
sleep

May affect
activity and
sleep

Frequent

Several times
per day

Table 1: Severity of Asthma
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Asthma is generally considered to be a costly illness, the total costs to society, whether direct,
indirect or intangible costs, are difficult to estimate, because of different disease characterizations
[7]
. Use of bronchodilators and anti-inflammatory drugs as current pharmacotherapy helps
primarily in leading to symptomatic improvement and suppression of airway inflammation along
with a decrease of bronchial hyper responsiveness [12].
It is generally characterized by airflow obstruction, hyper-responsiveness, and airway
inflammation: these problems generally lead to episodes of cough, breathlessness, and chest
tightness, particularly at night or early morning. It is triggered due to the consequence of complex
gene-environment interactions [13].
BA is a common airway disease in children and adults, and affects around 339 million people
worldwide. According to GINA, asthma affects about 1 – 18% of the population in different
countries. GINA defines asthma as a heterogeneous disease that is usually characterized by chronic
airway inflammation which includes symptoms such as wheezing, shortness of breath, chest
tightness, and cough with different intensities and timing.
GINA was initiated in 1989 to raise awareness among the public healthcare sectors and the general
public about asthma and its effects.
GINA has assessed asthma which involves the control, assessment of asthma along with its
treatment techniques, compliance of medications, and other comorbidities along with asthma
which can make way for a poor quality of life [5].
The prevalence of asthma is increasing due to the rapid industrialization of cities [14]. With the
development of India from an agricultural society into an industrializing country, the dense
population, the air pollution challenges, changing lifestyle, and the other environmental factors
very much affect the prevalence and incidence of asthma for everyone [15]. Due to the difference
in methodology of studies and wide geographical and environmental variations which include air
pollution, smoking, and other occupational exposures (factory, farming, or other occupational
exposures) in India, the estimated prevalence rate ranges from 2% to 23% [14]. Due to living in an
area with meagre medical facilities and inadequate financial resources, proper treatment of asthma
is lacking.
In India, there are vast economic, religious, racial and socio-political differences which affect the
treatment and its outcome. The reasons for poor prognosis are poor adherence, poor compliance,
inadequate education and poverty along with other secondary reasons. Due to the
Cultural diversity along with their lay beliefs of people can determine their disease acceptance and
therapy. Many people can be afraid of the current health care system or do not trust the medications
being prescribed. Poverty and inner-city living play an important role along with income in terms
of adherence and compliance to medications. Factors affecting adherence include financially
unstable populations who lack proper transport, are unable to pay for their medications, have
family problems, etc. thus leading to a decrease in patient QoL [16].
10

WHO (World Health Organization) has defined adherence to long-term therapy as “the extent to
which a person’s behaviour – taking medication, following a diet, and/or executing lifestyle
changes, corresponds with agreed recommendations from a health care provider”. [17]
Many advances have been seen in the clinical treatment of asthma over the past years. Even with
all the advances, the frequency and morbidity of asthma is continuously increasing. In general,
scientific evidence found on asthma along with its continuous negative effects seen in this society
has a key role in both the doctor’s and the patient’s performance [18]. The main reasons for this
have been proved to be due to inadequate education about the seriousness of their illness along
with poor compliance with their medications. Every patient should be thoroughly educated about
their disease by health professionals and should self-motivate to adhere to their medications thus
providing better health. This concept is referred to as self-efficacy according to WHO [17].

According to GINA guidelines 2019

Figure 2: GINA Personalized asthma management [5]
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Figure 3: Treatment of Bronchial Asthma [5]

*

Off-label; data only with budesonide-formoterol (bud-form)

†Off-label; separate or combination ICS and SABA inhalers
‡Low-dose ICS-form is the reliever for patients prescribed bud-form or BDP-form maintenance
and reliever therapy
#

Consider adding HDM SLIT for sensitized patients with allergic rhinitis and FEV1 > 70%
predicted

Treatment of asthma consists of many classifications such as Short-acting β2-agonists (SABA),
Long-acting inhaled β2-agonists (LABA), Inhaled corticosteroids (ICS), Leukotriene receptor
antagonist (LTRA), Methyl-xanthines, Oral corticosteroids, anti-histamines, expectorants,
mucolytic agents and Thromboxane A2 receptor antagonists (TXA2RA). The first-line therapy for
exacerbation of asthma includes SABA, corticosteroids, inhaled ipratropium bromide, and Oxygen
supplement. The most widely prescribed class is inhaled corticosteroids which are considered to
be most beneficial for the treatment of asthma as their direct mode of action is to the airways. The
reduction of unwanted systemic effects is seen as they reduce systemic exposure.

Actions useful in treating asthma include:
Increasing the number of β2-adrenergic receptors and improving the receptor responsiveness to β2adrenergic stimulation
12

Reducing mucus production and hypersecretion
Reducing BHR (Bronchial Hyper responsiveness), and
Reducing airway edema and exudation.
Lifestyle modifications for asthma include:
To quit smoking as the smoke irritates the airways
Drinking plenty of water especially during exercise to ensure hydration, keeping body cells
functioning and keeping the mucus of the airways loose
Avoiding environmental stimuli and allergens that might provoke an exacerbation
Use of air mask in case of dust exposure and
Taking plenty of rest in case of tiredness or shortness of breath[4]
Every patient must understand and follow the basic principles of self-management to prevent
exacerbation of their condition. The principles include:
Assessing the severity of asthma by interpreting key symptoms and peak flow meter readings.
Regular use of ICS and SABA on an as-needed basis for long term treatment.
In the case of severe asthma, systemic corticosteroids, long-acting β-agonists, and medical review
are suggested.
Unification of self-assessment and self-management with written guidelines for long-term
treatment as well as for acute treatment of asthma [19].
The economic cost of asthma is considered in terms of both direct (hospital admissions and cost
of medicines) and indirect costs (time lost from work, traveling cost and premature death, etc.) [20]
Direct medical costs contribute as the largest component of asthma medicines especially in North
America and Europe. Although in the Middle East and South Asia, costs such as outpatient costs,
doctor visits, and visits to Emergency Departments contributed to the larger proportion of total
costs. Indirect costs are often ignored in the cost estimates but studies report that these costs of
asthma contribute as a significant aspect of the economic burden [21].
Numerous studies have confirmed the inadequacy of asthma control. The severity of airway
diseases can be assessed using Health-related quality of life Questionnaire. Asthma can reduce the
quality of a life due to its physical and psychosocial complications.

13

14

15

16

Table 2: Different type of Asthma Questionnaires compared [22] [23] [24] [25]

Out of all the available questionnaires, AQLQ (S) was chosen as it is widely used and validated
for use in multiple countries. It has also been adapted to create versions for use in pediatric asthma
and rhinitis. Quicker and easier to use than original AQLQ.
Thus studies on AQLQ (S) were done which have shown how a treatment affects the patient’s life
either in a positive or negative. It includes a disease-specific 32 questions which include 4
domains: Symptoms, emotions, exposure to environmental stimuli, and activity limitations.
Patients rate each question according to what they experienced during the previous 14 days and
answer each question based on a 7 point scale system. The scoring was done by dividing the 32
items in the questionnaire into 4 domains where: Questions 1-5, 11, 19, 25, 28, 31, 32 was included
under the Activity limitation domain. Questions 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 29, 30 was
included for calculating Symptoms domain. Questions 7, 13, 15, 21 and 27 for Emotional function
domain. Questions 9, 17, 23, and 26 for the Environmental stimuli domain. A mean score was
taken for all the 32 questions on their responses by finding their mean: adding all the 32 values
and diving the value by 32. Thus the scores for each domain and overall mean would range from
1 to 7 where 1 indicates very poor QoL with severe impairments due to their asthma, whereas 7
indicates better QoL and no impairments due to asthma. The score 4 in the middle of the range
indicates a moderate degree of impairment.
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5. METHODOLOGY
5.1 Study Site: The study was conducted at Kasturba Hospital in the Department of Respiratory
Medicine.
5.2 Study design: Prospective observational study
5.3 Study period: 6 months (October 2019 to March 2020)
5.4 Sample Size: 46 patient files were collected
5.5 Ethical Approval:
The protocol for this study was approved by the Institutional Ethical Committee of Kasturba
Hospital, Manipal. (IEC: 544/2019)
5.6 Study criteria: The study group comprised of patients who came to the Out-Patient
Department in the Department of Respiratory Medicine who met the following criteria during the
study period:
5.6.1 Inclusion criteria:
Patients (age ≥ 18 years to ≤55 years) diagnosed with BA.
Patients of both genders.
Out-patients visiting to the Respiratory Department.
5.6.2 Exclusion criteria:
Patients with cardiovascular disease (Cardiac arrest, Arrhythmia, Congenital heart
disease, stroke)
Patient’s with hepatic and renal impairment.
Pregnant and lactating women.
Patients with neurological impairment.
5.7 Data source:
The study population broadly represents the South Indian population. All the necessary and
relevant data were obtained from the medical records, finance department and interviews of
patients diagnosed with BA.
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5.8 Study materials
Participant Information Sheet (PIS) - Used to provide necessary details (purpose,
benefits/risks, procedure) regarding the study.
Informed Consent Form (ICF) – An Informed consent form in Kannada or English was
obtained from each participant before study initiation.
Case Report Form (CRF) – To collect the necessary data from the patient records, an individual
data collection form was designed, which included: demographics, complaints on admission,
date of consultation, patient history (personal, family, social, medical and medication),
diagnosis, Arterial Blood Gas (ABG) reports, Pulmonary Function Test (PFT) reports, Mini
Peak Expiratory Flow Rate (PEFR) readings, allergy tests, laboratory findings, drug treatment
chart, cost per drug and cost of total therapy and follow up.
Asthma Quality of Life Questionnaire Standardized (AQLQ -S) – A questionnaire was
requested from the Juniper QoL network and their permission was obtained for administration
of the questionnaire to patients at first encounter. After the permission was granted, the original
copy of questionnaires was obtained from the Juniper QoL network including English and
Kannada versions of the questionnaire.
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5.9 Operation modality
The study was carried out in 6 main stages:
Stage 1: Designing data collection form
Stage 2: Evaluation of CRF design
Stage 3: Data collection
Stage 4: Administration of AQLQ (S)
Stage 5: Data entry
Stage 6: Evaluation & Analysis
STAGE 1: Designing a data collection form
Patient demographics, laboratory data, treatment chart, follow up and cost of therapy were taken
into consideration while designing a CRF.
STAGE 2: Evaluation of CRF design
The designed form was then evaluated by one internal and two external experts to ensure its
applicability, relevance, and accuracy according to the Head of Unit of Respiratory Department
and Head of Ayurveda Department.
STAGE 3: Data collection
1. Data of 46 patients was collected using the designed form.
2. After the informed consent was taken, the participant informant sheet was given.
3. The patient and/or patient party was asked a set of questions regarding their demographics
and relevant histories like social, medical, familial, etc.
4. Data were simultaneously recorded on printed copies of CRFs.
STAGE 4: Administration of AQLQ (S)
1. The questionnaire was administered to the patient at the first encounter.
2. The patient was asked to fill the questionnaire provided according to their symptoms, activity
limitation, emotional function, and environmental stimuli for the past two weeks.
3. According to their preferred language, English or Kannada questionnaires were given.
STAGE 5: Data entry
1. The collected data was checked for aberrancies and collated thereafter.
2. It was then entered into SPSS and re-checked for duplications.
3. This provides a platform through which the demographics and follow-up of the patient can
be assessed.
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STAGE 6: Evaluation & analysis
1. The data entered was analyzed based on the demographic information, ABG reports, PFT
reports, Mini PEFR readings, risk factors like social history, familial history, co-morbidities,
cost, and AQLQ (S).
2. Asthma Quality of Life Questionnaire (S) includes a disease-specific 32 questions which
include 4 domains: Symptoms, emotions, exposure to environmental stimuli, and activity
limitations. Patients rate each question according to what they experienced during the previous
14 days and answer each question based on a 7 point scale system. The scoring was done by
dividing the 32 items in the questionnaire into 4 domains where:

DOMAINS

QUESTION NUMBERS

NUMBER OF QUESTIONS

Activity limitation

1-5, 11, 19, 25, 28, 31, 32

11

Symptoms

12

Emotional function

6, 8, 10, 12, 14, 16, 18, 20, 22,
24, 29, 30
7, 13, 15, 21, 27

Environmental stimuli

9, 17, 23, 26

4

5

Table 3: Classification of AQLQ (S)
A mean score was taken for all the 32 questions on their responses by finding their mean:
adding all the 32 values and diving the value by 32. Thus the scores for each domain and
overall mean would range from 1 to 7 where 1 indicates very poor QoL with severe
impairments due to their asthma, whereas 7 indicates better QoL and no impairments due to
asthma. The score 4 in the middle of the range indicates a moderate degree of impairment.

3. The cost of therapy was taken from the finance department. The costs include cost per drug,
physician’s consultation fee, allergy test, PFT, or any other tests done for the patient.
4.

Data analysis was carried out at the end of data collection by using SPSS version 20.
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6.RESULTS
A prospective observational study was conducted where 57 files were collected out of which 11
files came under exclusion criteria, thus 46 patients’ data was collected. comprising of n=46
patients to evaluate the demographic parameters, comorbidities, drug utilization patterns, cost of
direct therapy and quality of life of each patient conducted in Department of Respiratory Medicine,
KMC, MAHE, Manipal
6.1 Demographic Overview
Male: 15 (32.6%)

Sex {n (%)}

Female: 31 (67.4%)
40.85 ± 10.02 years

Age in years (mean ± S.D.)
Co-morbidities {n (%)}

Present: 26 (56.5%)

Absent: 20 (43.5%)

Educational status {n (%)}

Literate: 43 (93.5%)

Illiterate: 3 (6.5%)

Allergy {n (%)}

Present: 13 (28.3%)

Absent: 33 (71.7%)

SPO2 {n (%)}

97.63 ± 0.96

MiniPEFR {n (%)}

304.47 ± 104.59

Pulmonary Function Tests

(mean ± SD)

FVC (pre)

77.77 ± 18.17

FVC (post)

74.23 ± 19.64

FEV1 (pre)

71.19 ± 19.42

FEV1 (post)

74.39 ± 19.33

FEV1/FVC (pre)

90.94 ± 11.03

FEV1/FVC (post)

93.52 ± 10.22

Overall AQLQ score

4.99 ± 1.24

Activity Limitation

4.83 ± 1.33

Symptoms

5.11 ± 1.41

Emotional Function

5.22 ± 1.31

Environmental Stimuli

4.66 ± 1.55
Table 4: Demographic Overview
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6.1.1 Sex
Out of n=46 patients enrolled in the study, 15 (32.6%) were male and 31 (67.4%) were female.
This shows a majority of subjects in the study were female.

SEX DISTRIBUTION
Male
33%

Female
67%

Figure 4: Sex Distribution
6.1.2 Age
Among the 46 patients, the majority of the patients fell under the age group of 31-40 years (30.4%),
followed by age groups 41-50 years (28.3%), 51-55 years (21.7%), and 18-30 (19.6%).

AGE
Percentage of Patients (%)

35

30.4

28.3

30
25
20

21.7

19.6

15
10

5
0
18-30

31-40

41-50

51-55

Age

Figure 5: Range of age of all patients
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Out of 46 patients, number of females below age 40 were 13 and number of females above 40
years of age were 18.

COMPARISON OF AGE VS SEX
Male

Female

14

12

12
9

Sex

10
8
6

5

4

6

5

4

4

1

2
0
18-30

31-40

41-50

51-55

Age

Figure 6: Age vs Sex
6.1.3 Co-morbidities:
Out of 46 patients, 26 (56.5%) had Bronchial Asthma with other co-morbidities and 20 (43.5%)
had only Bronchial Asthma.

CO-MORBIDITIES

Absent
44%
Present
56%

Present

Absent

Figure 7: Co-morbidities
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Among 46 patients, the co-morbidity which was mostly recorded was Allergic Rhinitis (26.1%)
followed by Others which include Post TB, Antral Ulcers, Bronchiectasis, Eczema, GERD, Iron
Deficiency Anaemia, Obstructive Airway Disease, Pulmonary Artery Hypertension, Post Nasal
Drip and Sinonasal polyposis (22%).

CO-MORBIDITIES

30

Percentae of patients (%)

26.1
25

22

20
15
10

13
8.7
6.5

6.5

Asthma-COPD
overlap

Hypertension

5

0
Diabetes
Rhinosinusitis
Mellitus Type 2

Other

Allergic Rhinitis

Co-morbidities

Figure 8: Different comorbidities
6.1.4 Educational status
Among n=46 patients, 43 (93%) were literate whereas 3 (7%) were illiterate.

EDUCATIONAL STATUS
7%

93%

Figure 9: Educational status
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6.1.5 Allergy
Out of n=46 patients, 13 (28%) had other allergies whereas 33 (72%) did not have any
allergies.

ALLERGY
Present

Absent

Present
28%

Absent
72%

Figure 10: Allergy
Among 46 patients, dust allergy (21.7%) was found to be present more than other allergies.

Percentage of patients (%)

OTHER ALLERGIES
25

21.7

20
15

10.9

10
5

13

13

6.5
2.2

2.2

2.2

2.2

0

Other allergies

Figure 11: Other Allergies
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6.1.6 ABG (Arterial Blood Gas) – SPO2 (% on RA)
Among 46 patients, 30 values (65.2%) were missing, hence out of 16 patients, 9 patients (19.6%)
had an SPO2 of 98% followed by 3 patients (6.5%) had 96%.

Percentage of patients (%)

ABG (SPO2)
65.2

70
60
50
40
30

19.6

20
10

6.5

4.3

96

97

4.3

0
98

99

Missing

SPO2 (%)

Figure 12: Arterial Blood Gas (SPO2)
6.1.7 Symptoms
Among n=46 patients, the most common symptoms were found to be Breathing problems (63%),
Coughing (60.9%), Wheezing (41.3%) and Nasal symptoms (21.7%). Others (37.2%) include
Aspergilloma surgery, Bloating, Chest pain, Chest paint, anxiety, Dyspnea, Exacerbation, Fever,
Headache, Joint pain, Left foot swelling, Sinus complaints, Sputum mucoid, Throat irritation and
Weakness.

SYMPTOMS
Percentage of patients (%)

70

60.9

63

Coughing

Breathing
Problems

60
50
37.2

40
30

41.3

21.7

20
10

6.5

0
Chest
tightness

Nasal
symptoms

Others

Wheezing

Symptoms

Figure 13: Symptoms
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6.1.8 Patient occupation
Out of n=46 patients, 20 (43.5%) were homemakers, 4 (8.7%) were laborers, 4(8.7%) were
farmers, 2(4.3%) were carpenters, 2 (4.3%) were lecturers, 2 (4.3%) were teachers and the rest
had other jobs. Other occupations include Bank employee, Cook, Coolie, Flower seller,
Housemaid, Mechanic, Mill worker, Nurse, Parlour, Railway employee, Service and Village
accountant.

Percentage of patients (%)

OCCUPATION
50
45
40
35
30
25
20
15
10
5
0

43.5

26.4

4.3

4.3

4.3

8.7

8.7

Occupation

Figure 14: Occupation
6.1.9 miniPEFR (Pulmonary Expiratory Flow Rate)
Among n = 46 patients, the mean miniPEFR was found to be 304.47 ± 104.59.
6.1.10
Pulmonary Function Tests:
FEV1/FVC (post) values show that mean ± SD is 93.53 ± 10.22 which indications the minimum
value is 83.3 and the maximum value is 103.74. As the ratio is not less than 70%, there is no
obstruction.
Tests
Mean ± SD (%)
FVC (pre)

77.77 ± 18.17

FVC (post)

74.23 ± 19.64

FEV1 (pre)

71.19 ± 19.42

FEV1 (post)

74.39 ± 19.33

FEV1/FVC (pre)

90.94 ± 11.03

FEV1/FVC (post)

93.52 ± 10.22

Table 5: Pulmonary Function Tests (Mean ± SD)
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Among n = 46 patients, FEV1 pre values show that 45.6% of patients have a value less than 80%,
hence for these patients, an obstruction is seen whereas 21.7% had values above 80% and 32.6%
values were missing.
FVC
(pre) FVC (post)

FEV1 (pre)

FEV1 (post)

FEV1/FVC
(pre)

FEV1/FVC
(post)

<60% (Severe
Persistent)

10.9

8.7

13

17.4

60-80% (Moderate
Persistent)

28.3

32.6

32.6

32.6

15.2

8.7

>80% (Mild
Persistent (or)
Intermittent)

28.3

26.1

21.7

17.4

52.2

58.7

Missing

32.6

32.6

32.6

32.6

32.6

32.6

Table 6: Pulmonary Function Tests (Percentages)

Percentage of means of values (%)

MEANS OF PFT VALUES
100
90
80
70
60
50
40
30
20
10
0

71.19

74.23

74.39

77.77

FEV1 (pre)

FVC (post)

FEV1 (post)

FVC (pre)

90.94

93.52

FEV1/FVC
(pre)

FEV1/FVC
(post)

PFTs

Figure 15: PFT values
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6.2 Drug Utilization Evaluation
This table shows different therapies given to the patients, among which 23 patients (50%) were
given a five-drug therapy, 7 patients (15.2%) were given a four-drug therapy, 6 patients (13%)
were given three-drug therapy, 4 patients (8.7%) were given six-drug therapy, 4 patietns (8.7%)
were given a two-drug therapy, 1 patient (2.2%) was given seven-drug therapy and 1 patient
(2.2%) was given a single-drug therapy.
Single
Therapy

Dual
Therapy

Triple
therapy

Quadruple
therapy

Quintuple
therapy

Sextuple
therapy

Septuple
therapy

1

4

6

7

23

4

1

Table 7: Different drug therapies

PERCENTAGE OF DIFFERENT DRUG THERAPIES
2.2

8.7

2.2

8.7

Single
13

Dual
Triple
Quadruple

15.2

Quintuple
Sextuple

50

Septuple

Figure 16: Different drug therapies
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6.2.1 Medications
Among 46 patients, 43 patients (93.5%) were given LABA + ICS combination, 37 patients
(80.4%) were given LTRA + Anti-histamine combination, 27 patients (58.7%) were given
Corticosteroids. These three were the main drugs given to patients for the treatment of Asthma.
The combination of LABA + ICS which was prescribed to the patients consisted of Formoterol
+ Budesonide for almost all patients. According to FDA, using LABAs alone to treat asthma
without an ICS to treat lung inflammation is associated with an increased risk of asthma-related
death. ICS alone helps in decreasing the inflammation in the lungs and LABAs help the muscles
around the airways to stay relaxed to prevent symptoms such as wheezing, coughing, chest
tightness, and shortness of breath. In four trials conducted by the FDA, it showed that LABA+ICS
combination medicines were more effective in decreasing asthma attacks compared to ICS
alone.[26]

Percentage of Patients (%)

MEDICATIONS
100
90
80
70
60
50
40
30
20
10
0

93.5
80.4
58.7

6.5

8.7

67.4

15.2

Classes of Drugs

Figure 17: Medications
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6.2.2 Types of therapy compared with different aspects of QoL
This table shows the overall AQLQ score and other domains of QoL compared with different
therapies. This shows that patients receiving Triple therapy had the highest QoL as compared to
other therapies.

ACTIVITY
LIMITATIO
N
5.82

SYMPTOMS

EMOTIONAL
FUNCTION

SINGLE

OVERAL
L AQLQ
SCORE
5.87

6.17

5.8

ENVIRONME
NTAL
STIMULI
5.25

DUAL

4.58 ± 0.94

4.27 ± 1.40

4.39 ± 1.26

4.59 ± 0.92

5.56 ± 1.42

TRIPLE

5.50 ± 1.44

5.30 ± 1.44

5.61 ± 1.64

5.83 ± 1.90

5.27 ± 1.93

QUADRUPLE

5.24 ± 1.65

4.9 ± 1.76

5.49 ± 1.90

5.40 ± 1.96

4.78 ± 2.00

QUINTUPLE

5.01 ± 1.04

4.96 ± 1.36

5.13 ± 1.16

5.23 ± 1.71

4.38 ± 1.39

SEXTUPLE

4.66 ± 0.86

4.32 ± 0.62

4.94 ± 0.74

4.95 ± 1.43

4.31 ± 1.57

SEPTUPLE

1.94

1.64

1.66

3.2

3.75

Table 8: Comparison of therapies and QoL

6.2.3 Comparison of age groups with different aspects of QoL
Among 46 patients, patients in the age group of 31 – 40 had the highest QoL as compared to
others.
AGE

ACTIVITY
LIMITATION

SYMPTOMS

EMOTIONAL
FUNCTION

18 – 30

OVERALL
AQLQ
SCORE
4.97 ± 0.90

4.95 ± 0.93

5.16 ± 0.97

4.93 ± 1.33

ENVIRON
MENTAL
STIMULI
4.28 ± 1.25

31 – 40

5.53 ± 1.41

5.45 ± 1.37

5.56 ± 1.68

5.44 ± 1.69

5.32 ± 1.42

41 – 50

4.34 ± 1.16

4.08 ± 1.42

4.48 ± 1.31

4.97 ± 1.15

4.03 ± 1.50

51 – 55

5.09 ± 1.07

4.82 ± 1.12

5.27 ± 1.34

5.45 ± 0.94

4.9 ± 1.80

Table 9: Comparison of age groups and QoL
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6.2.4 Comparison of comorbidities with overall AQLQ score
Among 46 patients, 26 patients had comorbidities whereas 22 did not. Patients without
comorbidities had a better QoL (5.17 ± 1.38) than in patients with comorbidities.
Comorbidities

N

Mean ± SD

26
4.86 ± 1.12
Overall AQLQ
With
score
20
5.17 ± 1.38
Overall AQLQ
Without
score
Table 10: Comparison of comorbidities and Overall AQLQ score
6.2.5 Comparison of gender and different aspects of QoL
Among 46 patients, 15 were male and 31 were female. This table shows the mean ± SD for the
overall AQLQ score and other domains of QoL. This shows that females had a better QoL than
males.

Sex

Overall
AQLQ score

Activity
Limitation

Symptoms

Emotional
Function

Environmental
Stimuli

Male

4.89 ± 1.21

4.47 ± 1.22

5.03 ± 1.31

5.29 ± 1.48

4.75 ± 1.72

Female

5.04 ± 4.99

4.99 ± 1.36

5.15 ± 1.47

5.19 ± 1.25

4.62 ± 1.49

Table 11: Comparison of gender and QoL
Comparison of mean scores of overall AQLQ score and other domains of QoL with
gender
This graph shows that in all domains except environmental stimuli, females have a higher QoL
than males.

MEAN SCORES OF QOL AND GENDER

Sex

Male
5.4
5.2
5
4.8
4.6
4.4
4.2
4

5.04

4.99

4.89

Female

5.03

5.15

5.29

5.19
4.75

4.62

4.47

Overall AQLQ
score

Activity Limitation

Symptoms

Emotional
Function

Environmental
Stimuli

QoL scores

Figure 18: Comparison of mean scores of QoL and Gender
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6.2.6 Comparison of educational status and various aspects of Quality of Life
Among 46 patients, mean scores of Literate patients had a better Quality of Life than Illiterate
patients in Overall AQLQ score (5.02), Activity Limitation (4.84), Symptoms (5.14),
Emotional function (5.26) and Environmental stimuli (4.68).

EDUCATIONAL STATUS VS QOL
Literate

Illiterate

5.4

Educational status

5.2

5.264
5.1384
5.0163

5
4.8

4.8421
4.6633

4.75

4.6067

4.6

4.6

4.6781
4.4167

4.4
4.2
4
3.8
Overall AQLQ score Activity Limitation

Symptoms

Emotional Function

Environmental
Stimuli

QoL

Figure 19: Comparison of Educational status and QoL
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6.3 Individual drug cost, lab charges and total cost
Among 46 patients, the average total cost was found to be ₹2252.24 ± 1056.56, average drug cost
was found to be ₹1142.15 ± 484.35 and average lab charges were found to be ₹920.33 ± 902.31.
Total cost

Drug cost

Lab charges

2252.24 ± 1056.56 1142.15 ± 484.35

Mean ± SD

920.33 ± 902.31

Table 12: Mean ± SD of different costs

6.3.1 Comparing costs of patients with and without allergic rhinitis
Among 46 patients, 12 patients had allergic rhinitis whereas 34 did not. This graph shows that
patients with allergic rhinitis had drug costs, lab charges, and total cost higher than in patients
without allergic rhinitis.

COMPARING COSTS OF PATIENTS
WITH AND WITHOUT ALLERGIC
RHINITIS
Allergic rhinitis

Yes

No

3500
2861.25

3000
2500

2037.2941

2000
1500
1000

1462

1210.9167
1029.2647

817.7647

500
0
Drug cost

Lab charges

Total cost

Cost

Figure 20: Comparison of costs of patients with and without allergic rhinitis
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6.3.2 Comparison of costs of patients with and without comorbidities
Among 46 patients, 26 patients had comorbidities whereas 22 did not. This graph shows that the
drug costs and total cost in patients with comorbidities were higher than in patients without
comorbidities. But lab charges were slightly higher in patients without comorbidities.

COSTS VS COMORBIDITIES
With

Without

2344.2308
2132.65

Comorbidities

2500
2000
1500
1000

880.8846 971.6

1276.4615
967.55

500

0
Lab charges

Drug cost

Total cost

Costs

Figure 21: Comparison of costs of patients with and without comorbidities

6.3.3 Comparison of costs of patients with and without allergies
Among 46 patients, 13 patients had allergies whereas 33 did not. This graph shows that patients
with allergies had lab charges, drug costs and total costs higher than patients without allergies.

ALLERGY VS. COST
Present

Absent

3500

3128.1538

3000

Allergies

2500
2000
1500
1000

1907.1818

1740.3846
1190.9231
1122.9394
597.2727

500
0
Lab charges

Drug cost

Total cost

Costs

Figure 22: Comparison of costs of patients with and without allergies
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7. DISCUSSION
7.1 Demographics details of the patients
The aim of our study was to synthesize the evidence that can influence QoL in adults with asthma.
Symptoms such as breathlessness, coughing, wheezing and chest tightness can influence an
individual’s life, resulting in activity limitation, emotional, financial and medication related
burden that can negatively impact QoL.
The incidence and prevalence of asthma in India is affected because of its immense geographical
and environmental diversities. According to different studies most patients experience
uncontrolled symptoms. Our study evaluated the common problems affecting the QoL of BA,
with stratification for several possible factors of impairment (age, sex, education status,
occupation, allergy, respiratory rate, oxygen saturation, and presence of co-morbidities).
A total of 46 patients were enrolled in the study. It was found that 67% of the study population
were females and 33% were males. Number of females below 40 years of age were 13 and
number of females above 40 years of age were 18.
Our study showed that the incidence of asthma was predominant in females than in males. Similar
findings were seen in the study conducted by Morris M.J. in 2019 which stated that the majority
of adult-onset cases in persons older than 40 years of age occurred in females [27].
The mean age in our study was found to be 40.85 ± 10.02, which was different from the other
studies carried across the country. This could be due to the fact that our study has only 46 patients.
7.2 Quality of Life of patients
Patients diagnosed with asthma experience several problems concerning everyday activities and
functions, which adversely affects their AQLQ. Patient’s problems relating to their therapy
cannot be credited to the lack of their knowledge on the disease and/or lack of adherence alone.
The decision-making process of adults and caregivers is based on their population, experiences,
and preferences and therefore patients should be viewed as active participants in care.
The purpose of our study was to find out the QoL (using AQLQ) of BA patients at baseline. The
study patients visited the respiratory department, who had confirmed diagnosis of BA and
sometimes with co-morbid conditions like hypertension, diabetes mellitus, allergies, post-TB,
antral ulcers, etc.
The sample size in our study was 46 and AQLQ was administered to all patients meeting the
inclusion criteria.
The symptoms of asthma showed a distressing level (5.11 ± 1.41) which mainly included
Breathing problems (63%), Coughing (60.9%), Wheezing (41.3%), and Nasal symptoms
(21.7%).
A study from Italy found that QOL (as evaluated by AQLQ) is significantly impaired in the group
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of patients with dyspnea, chest tightness, and asthmatic crisis. [28]
As a part of the TENOR study conducted in the US, including adolescents and adults, Luskin et
al. showed that asthma exacerbation frequency and severity and the number of triggers at baseline
were strongly associated with patients’ asthma-related QOL. They also identified specific asthma
triggers that were strongly associated with QOL and risk of future exacerbations. [29]
In a study from England, a mini Asthma Quality of Life Questionnaire (mAQLQ), and Asthma
Symptom Utility (ASUI) measures were significantly worse for patients suffering exacerbations
compared to those without, however, no data about the domains were measured in this work. [30]
The study showed that there was a moderate activity limitation (4.83 ± 1.33), where the
population had difficulties in performing activities such as climbing stairs, walking, sleeping,
hurrying, exercising, shopping, housework, talking, exposure to environmental dust/smoke.
When measuring the emotional function of the patients 5.22 ± 1.31, the troubling factors were
found to be frustration, concerned about having asthma and the use of medications, afraid of
gasping for breath, and afraid of not having medication available.
Environmental stimuli affecting BA patients (4.66 ± 1.55) was the lowest score through all the
categories, and thus affecting the patient’s QoL. The presence of stimuli like exposure to cigarette
smoke, dust, seasonal pollens, air pollution, exposure to strong smell or perfume were found to
be the contributing factors. This could be improved by giving proper awareness among patients
about stimulating factors by the nurses, pharmacists, and physicians.
In a study done by Uchmanowicz B., et al, results showed that QoL scores can be impaired by
Frequency of the symptoms like chest tightness and shortness of breath. Among the domains
measured, the most affected were activity limitation and environmental stimuli thereby reducing
overall QoL. [31]
In a study done by Kotwani A. et al, Overall AQLQ score was found to be 3.68 ± 0.78, Activity
Limitation was 3.7 ± 1.04, Symptoms was 3.84 ± 0.81, Emotion function was 3.9 ± 0.68 and
Environmental stimuli was found to be 2.95 ± 0.28. This study showed a moderate to severe
impairment as the values were closer to 1 which indicates severe impairment whereas our study
results can be classified as moderate impairment as the values are closer to 4 which indicates
moderate impairment [32].
The baseline activity limitation in males was found to be high than in females. This may be due
to the measurement of activity limitation set by the AQLQ, other than measuring the type of work
each gender does.
There is a difference in the type of work done by males and females from the demographics of
the study population.
The emotional function in males was higher than in females, this could be because females might
perceive the same level of airflow obstruction differently than males and its impact on their daily
living. Another possible reason can be due to differences in their psychological, biological, or
cultural distinction between the two. The environmental stimuli and symptoms were higher in
males than in females. This could be because of a higher number of females in the study group
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and also due to repeated exposure to the same stimuli like kitchen smoke and house dust.
The overall AQLQ score was high in the 31-40 age group patients. This could have been due to
a proper understanding of the severity of the disease, proper use of medications and avoidance
of allergens. Most of the patients above 40 years didn’t understand the proper use of inhalers and
avoidance of allergens. Patients without comorbidities had better QoL. No previous studies were
done comparing various aspects of QoL between males and females.
7.3 Drug Utilization Evaluation
Overall DUE showed that ICS+LABA, was the drug of choice for asthmatic patients, probably
due to convenience, safety, and effectiveness. The main three drugs given to patients for the
treatment of Asthma were LTRA+ICS combination (93.5%), LTRA+Anti-Histamine
combination (80.4%), and Corticosteroids (58.7%). From 2019, for safety, GINA no longer
recommends starting treatment with SABA and recommends all adults and adolescents with
asthma to receive ICS containing controller treatment to reduce the risk of serious exacerbations
and to control symptoms. The new ICS controller options include low dose ICS-LABA, regular
ICS or ICS-LABA every day and maintenance and reliever treatment with ICS-LABA [33].
7.4 Cost of therapy
BA is found to be the commonest inflammatory condition in developed and developing countries
and it creates a substantial burden on individuals and families and thereby results in underdiagnosis and under-treatment in low-income developing countries like India. The average total
cost of treatment, drug cost and lab charges in 46 patients were found to be 2252±1057, 1142.15
± 484.35 and 920.33 ± 902.31 respectively. In a study done by Aneeshkumar S. et al, mean annual
costs were taken for medication cost and lab charges which were found to be 7427/year and
1103/year [34]. This disparity in cost could be because physicians prescribed the drugs according
to the severity of diseases, co-morbidities, patient affordability, the need of preventive
medications, different types of medical devices, and different medical tests.
The average cost of therapy was found to be higher in the case of patients with co-morbidities.
In a study conducted by Chen W. et al, 13% of patient costs were attributable to asthma and 65%
were attributable to comorbidities [35]. This could be due to the additional burden from
medications that were needed for the treatment, prevention, and control of comorbid conditions.
Patients with allergies and allergic rhinitis had drug costs, lab charges, and total cost higher than
in patients without allergies and allergic rhinitis.
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LIMITATIONS
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8. LIMITATIONS
The cost of medicines was not uniform, varied depending on pharmacies.
Duration of medicines not prescribed for some patients.
Our prospective study was limited by the lack of lab values (LFTs, peak flow measurement)
that would have helped stage asthma as per GINA guidelines.
Patients don’t come for review thereby adherence is not well understood
Small sample size
The study included patients that had BA and other co-morbid conditions. The presence of
other co-morbid conditions may impact the
Patients QoL and cost of therapy.
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9. CONCLUSION
BA affects the physical, emotional, and social aspects of the life of a patient. Therefore,
maintenance of a good QoL is required to prevent the risk of exacerbation and mortality
associated with the disease.
This study showed that sociodemographic factors such as age, gender, co-morbidities,
education level and occupation status of the patients has an impact on all the domains of QoL.
The QoL assessment with domains like symptoms, emotional function, and activity
limitations were found to be severe and environmental stimuli were found to be moderate.
This is an important tool in perceiving the impact of the BA on the day to day life of patients
suffering from this condition.
The study found that the total cost of therapy was higher in patients with co-morbid
conditions. The knowledge obtained from the present study can further help to plan
interventions needed to improve the effective management of bronchial asthma.
Along with conventional strategies and guideline-based treatments, other nonpharmacological therapies can be implemented to achieve better outcomes.
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10. FUTURE DIRECTIONS
Proper therapeutic interventions and patient education can improve QoL.
Having a national dashboard for asthma and allergies can be beneficial to
track asthma progress.
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APPENDIX I: CTRI REGISTRATION NO. & IEC CERTIFICATE
CTRI REGISTRATION NUMBER: CTRI/2019/10/021481
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APPENDIX ll a: ADULT PIS (ENGLISH)

PARTICIPANT INFORMATION SHEET
Project title: Comparative study of Drug Utilization and effects in Ayurveda and Conventional
treatment in Bronchial Asthma.
IEC No.:
Sponsor Name: NA
Language: English
Principal Investigator: Ananya A Nayak
Designation: Student
Hospital: Kasturba Hospital, Manipal
Mobile number: 7975827672
Please read this form carefully. If you don’t understand the language or any information in this
document, please discuss with study doctor. Your participation in this study is voluntary, and you can
enquire about all details before giving your written consent to participate in this study.

1. Introduction to the research study:
You are invited to participate in this study because you have Bronchial Asthma. This study involves the
use of a drug as prescribed by your treating physician. This is an observational study.

2. Purpose of the study:
1. To look at the safety/efficacy of drugs as prescribed by your treating physician in treatment of
Bronchial Asthma.
2. To study the quality of life among Bronchial Asthma patients.
3. Who can take part?
Inclusion criteria: Those patients who are diagnosed as Bronchial Asthma who are above 18
years of age group up to 55 years of age, patients of both genders and out-patients visiting
the Respiratory and Ayurveda departments.
Exclusion criteria: Patients with CV disorders, hepatic and renal impairment, those who are
pregnant, lactating and patients with neurological disorders.
4. Information about the study (as a whole):
Sample size: Minimum of 125 patients individually in Ayurveda and Conventional treatment
in Bronchial Asthma. (Total: Minimum 250)
5. What will happen to you (the individual participant) during the study?
Please provide information as enquired by the clinical pharmacist/physician. Your identity will
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remain confidential.
A questionnaire will be provided to assess the quality of life.
6. You’re (the individual participant) role/responsibility in the study:
Provide accurate information whenever asked.
Inform the study doctor about any problem/side effects experienced during the treatment.
Follow the investigators instruction.
If you want to discontinue from the study, study doctor to be informed.

7. What are the risks?
Minimal risks
8. What are the potential benefits of participating in the study?
There is no direct or indirect benefit to the participant. However, if you take part in this study
you may help other patients with Bronchial Asthma by contributing to the knowledge.
9. What are the alternative treatments available?
The study does not involve or influence any treatment, hence this section is not applicable.
10. Cost of participating in the study:
No additional cost for being a part of this study. But you have to pay for your own drugs,
tests and procedures required to be done during the study period as this is an observational
study.
11. Compensation for injury:
If a problem arises as a direct result of the study procedure (administering questionnaire and
data from the file), the researcher will ensure that adequate care is provided to you.
12. Confidentiality of information:
Information from the study records including your name, address, medical records, results of
tests, study results will be kept confidential and will be reviewed only by authorized personnel
from the sponsor or their representative, Ethics Committee or regulatory bodies. The data
will not be made available to another individual unless you specifically give permission in
writing. Information and results from this study may be presented at meetings or published in
journals without including your name and personal identifications.
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13. New information about the study:
Any new information available during the course of the study will be informed to you if it has
relevance to your decision regarding continuing in the study. Results of your participation will
be disclosed to you if you indicate your desire for it.
14. Voluntary participation:
Your participation in this study is voluntary; you may decline to participate at any time and you need
not give any reason for the same, and such withdrawal shall be without penalty and without loss of
benefits to which you are otherwise entitled. If you withdraw from the study prior to its completion,
you will receive the usual standard of care for your disease, and your non participation will not have
any adverse effects on your subsequent medical treatment or relationship with the treating physician.

If you withdraw from the study before data collection is completed, your data collected until
you indicated withdrawal will be used in the study report. Sponsor or the investigator may
stop the research or your participation in it at any time for some or other reason without your
permission.
15. Whom to contact in case of any questions:
If you experience adverse effects as a result of participating in this study, you may contact the
Principal Investigator (Ananya A Nayak) as detailed above.
If you have any questions about the informed consent process or your rights as a participant,
you may contact the Member Secretary of the Kasturba Medical College and Kasturba Hospital
- Institutional Ethics Committee at Room 22, Ground floor, KMC Faculty Rooms, adjacent to
KMC Administrative Block, Kasturba Medical College, Manipal - 576104. Phone: 0820 29
33522. Timings: 9:00 AM to 5:00 PM.
If you have any questions about this form or any study related issue, you may also contact the
following person.
Name: Dr. Girish Thunga
Address: Department of Pharmacy Practice, MCOPS, MAHE, Manipal
Telephone No: +919880151127
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APPENDIX III a: ICF ADULT (ENGLISH)
Project title: Comparative study of Drug Utilization and effects in Ayurveda and
Conventional treatment in Bronchial Asthma
I confirm I have read the Participant Information Sheet for the above study and
its contents were explained and I have had the opportunity to ask questions and
received satisfactory answers.
I understand that my participation in the study is voluntary and that I have the
right to withdraw at any time without giving any reason, without my medical
care or legal rights being affected.
I agree to take part in the above study. I confirm that I have received a copy of
the Participant Information Sheet along with this signed and dated informed
consent form.
Name of the Research Participant:
Age of the Research Participant:
Address of the Research Participant:
Occupation:
Annual Income of the Participant:
Name & address of the nominee(s) and his relation to the Participant:
________________________________________________________________
________
__________________________
Signature of the research subject

_________
Date

__________________________
Name & Signature of the witness

_________
Date

_______________________________________________
Name & Signature of the person explaining the consent

_________
Date
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APPENDIX IV: ADULT CRF
STUDY: Comparative study of Drug utilization and effects in Ayurveda and Conventional treatment in
Bronchial Asthma
DEPARTMENT OF PHARMACY PRACTICE, KASTURBA HOSPITAL, MANIPAL
HOSP. NO:
AGE:

SEX: M/F :
WEIGHT:

COMPLAINTS ON ADMISSION:
SYMPTOMS:

DOA:
HEIGHT:

BMI:

DOD:

OTHERS:

Wheezing
Coughing
Breathing problems
Chest tightness
MEDICAL HISTORY:
MEDICATION HISTORY:
PERSONAL HISTORY:
FAMILY HISTORY:
EDUCATIONAL STATUS:
PREVIOUS ALLERGIES:

PHYSICAL EXAMINATION:
GENERAL
VITAL SIGNS HEENT
CVS
RS
GIT
GU
EXT
CNS
ROUTINE BIOCHEMICAL INVESTIGATIONS
Urea:
RBS:
Alb:
S.Cr :

Tch :

Na:
K:

TGs :
T Bili:

FBS:

D Bili:

PPBS:

T. Prot:

ABG REPORTS

Glob:
AST:
ALT:
ALP:

PFT REPORTS

RBC :
WBC:
N:
L:
M:
E:
B:

Retics:
Hb:
PCV:
MCV:
MCH:
MCHC:
ESR:

Mini PEFR readings

ALLERGY TEST:
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OTHERS:
FINAL DIAGNOSIS:
DRUG TREATMENT CHART:
DRUG WITH DOSE & ROUTE
GENERIC NAME

Follow up:

BRAND NAME

COST PER DRUG
1

2

3

COST OF TOTAL THERAPY

Mobile no.:
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APPENDIX V a: Asthma Quality of Life Questionnaire Standardized (12 years and above)
English
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APPENDIX V b: Asthma Quality of Life Questionnaire Standardized (12 years and above)
Kannada
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